Aptose Shares Surge Following Encouraging Pre-Clinical Data on CG’806

Aptose Biosciences (APTO) shares jumped in Monday trading after the Canadian-based clinical-stage biotechnology company said preclinical data demonstrated the robust cell killing ability of CG’806, a pan-FLT3/pan-BTK inhibitor, in multiple types of AML and B-cell malignancies.

Data further demonstrated CG’806 targets multiple pathways and overcomes drug resistance seen with other inhibitors, the company said in a statement.

“As a pan-FLT3/pan-BTK multi-kinase inhibitor that can eliminate tumors in the absence of toxicity in animal models, CG’806 has demonstrated the ability to kill a broad range of AML and B-cell malignancies through inhibition of multiple oncogenic pathways,” CEO William Rice said in a statement. “We are eager to pursue its clinical development.”

Shares rose 9% to $3.59 at 3:33 pm ET in New York.

Leave a Reply

Your email address will not be published. Required fields are marked *